ClinicalTrials.Veeva

Menu

Survival Rate After TheraCal PT Pulpotomy Versus MTA Pulpotomy in Children With Vital Primary Molars.

Cairo University (CU) logo

Cairo University (CU)

Status

Unknown

Conditions

Reversible Pulpitis

Treatments

Drug: MTA
Drug: TheraCal PT

Study type

Interventional

Funder types

Other

Identifiers

NCT04617600
14422019496708

Details and patient eligibility

About

The aim of the study is to assess the effect of TheraCal PT pulpotomy versus MTA pulpotomy on the survival rate of cariously exposed vital primary molars.

Full description

for both interventions ,

  1. Informed consent from participating parents.
  2. Baseline records photographs, percussion test, periapical radiograph and personal data collection.
  3. Allocation (concealed by withdrawing a sealed opaque envelope containing eight times folded paper containing the type of dressing material that will be used then writing patient name and I.D. on it and will be opened after performing the access cavity).
  4. Diagnostic chart with personal, medical and dental history will be filled.
  5. Clinical examination will be performed to assess the clinical inclusion criteria. (Pulpal and periapical diagnosis is established after clinical examination).
  6. Preoperative and Postoperative photographs will be taken.
  7. The radiographic examination will be performed by taking periapical x-ray using (parallel technique) through machine to assess the inclusion criteria. The preoperative radiograph will serve as a reference for the follow-up radiographs. Standardization of the technique to avoid any distortion in the vertical dimension and to provide reproducible images using x-ray holding device.
  8. Preoperative and postoperative radiograph will be taken by parallel technique using extension cone paralleling (XCP) film holder.
  9. Administration of inferior alveolar nerve block (Septodont, Scandonest® 2% L Mepivacaine hydrochloride (HCl). 2% and Levonordefrin 1:20,000 Injection, U.S.P.) at the side of the affected tooth.
  10. Application of rubber dam for isolation, then a standardized pulpotomy procedure will be performed using a large sterile round end bur in a high-speed handpiece with copious irrigation, a sharp spoon excavator will remove pulpal tissues to the orifice level. Hemostasis will be achieved by the application of a wet cotton pellet.

Children will then be allocated into either one of the groups alternatively depending on the pulpotomy medicament used as follows:

  • Group I (Experimental group) TheraCal PT pulpotomy.
  • Group II (Control group) MTA pulpotomy.

Group I (Experimental group) TheraCal PT:

  1. After complete hemostasis, TheraCal PT (BISCO Dental Products, Schamberg illinois (IL), U.S.A.) will be applied according to the manufacturer's instructions and gently placed over the pulp stumps to a thickness of 2mm then the rest of the pulp chamber will be filled with glass ionomer cement.
  2. Tooth will then be restored with stainless steel crown.

Group II (Control group) MTA pulpotomy:

  1. After complete hemostasis, MTA+ Curamed (ul. Kwiatkowskiego 1, 37-450 stylosa Wola, Polka) will be manipulated in the ratio of 3:1 (powder: liquid) to obtain a putty mix. This mix will be placed over the radicular pulp with the help of a suitable sterile amalgam carrier. Gentle condensation of the mix will be done in the pulp chamber with a moistened cotton pellet, followed by application of glass ionomer cement.
  2. Tooth will then be restored with stainless steel crown.

Enrollment

20 estimated patients

Sex

All

Ages

4 to 7 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Aged 4 to 7 years , in good general health and mentally free.
  • The parents provided written informed consent.
  • Cariously exposed primary molars with reversible pulpitis.
  • Teeth should be vital.
  • Restorable teeth.
  • Hemostasis achieved after complete pulpotomy

Exclusion criteria

  • With systemic disease.
  • Physical or mental disability.
  • Unable to attend follow-up visits.
  • Refusal of participation.
  • Previously accessed teeth.
  • History of spontaneous or prolonged pain.
  • Swelling, tenderness to percussion or palpation, or pathological mobility.
  • Pre-operative radiographic pathology such as resorption(internal or external),per-radicular or furcation radiolucency.
  • Haemorrhage control is unachievable after pulpotomy.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Triple Blind

20 participants in 2 patient groups

Mineral trioxide aggregate (MTA)
Active Comparator group
Description:
Survival rate of cariously exposed vital primary molars using MTA+ Curamed (UI, Kwiatkowskiego 1, 37-450 Staleya Wola, Polka)
Treatment:
Drug: MTA
TheraCal PT
Experimental group
Description:
Survival rate of cariously exposed vital primary molars using TheraCal PT (BISCO Dental Products, Schamberg IL, U.S.A.)
Treatment:
Drug: TheraCal PT

Trial contacts and locations

0

Loading...

Central trial contact

Reem Mohamed Gaber, B.Sc; Passant Nagi, PHD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems